$599
Bolus Insulin, DPP-IVi, GLP-1RA, GLP-1RA + Basal, SGLT2i, Topics

Lilly Q1 ’17 Earnings Update

Lilly hosted its Q1 ’17 earnings call and provided an update to its diabetes portfolio including pipeline and LCM activities.

This content is for Read Less members only.
Register
Already a member? Log in here
OR
Return to Home